Akero therapeutics, inc. (AKRO)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Dec'18
Assets
Current assets:
Cash and cash equivalents

47,245

64,788

147,835

162,654

75,975

Short-term marketable securities

78,040

71,612

-

-

0

Prepaid expenses and other current assets

933

1,649

2,238

454

1,156

Total current assets

126,218

138,049

150,073

163,108

77,131

Right of use asset

226

-

-

-

-

Restricted cash

-

-

60

60

-

Other assets

177

69

10

-

20

Total assets

126,621

138,118

150,143

163,168

77,151

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

1,535

947

93

3,248

1,373

Accrued expenses and other current liabilities

6,751

8,422

6,632

1,492

969

Total current liabilities

8,286

9,369

6,725

4,740

2,342

Other liabilities

12

23

34

39

-

Total liabilities

8,298

9,392

6,759

4,779

2,342

Redeemable convertible preferred stock (Series A and B), $0.0001 par value; no shares authorized, issued and outstanding as of December 31, 2019; 64,730,410 shares authorized, issued and outstanding as of December 31, 2018; aggregate liquidation preference of $0 and $96,358 as of December 31, 2019 and December 31, 2018, respectively

-

-

-

-

124,728

Stockholders’ equity:
Common stock, $0.0001 par value, 150,000,000 shares authorized as of March 31, 2020 and December 31, 2019; 28,671,222 and 28,567,837 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively

3

3

3

3

-

Additional paid-in capital

260,481

259,049

258,090

257,541

36,646

Accumulated other comprehensive gain (loss)

45

-6

-

-

-

Accumulated deficit

-142,206

-130,320

-114,709

-99,155

-86,565

Total stockholders’ equity

118,323

128,726

143,384

158,389

-49,919

Total liabilities and stockholders’ equity

126,621

138,118

150,143

163,168

77,151